Key points of the changes of FDA guidance on BA/BE studies in INDs/NDAs
LI Li
ZHANG Yu-hu
Keywords：bioavailabilitybioequivalenceFDA guidanceNDAIND
Publication Date：2014-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)